Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 6, 2013, Pages 1441-1447

  Hornstrup, Louise S ^a,d   Frikke Schmidt, Ruth ^a,c,d   Nordestgaard, Borge G ^a,b,c,d   Tybjcrg Hansen, Anne ^a,b,c,d  

^a Department of Clinical Biochemistry ^*  (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amyloid; Amyloid angiopathy; Cerebrovascular disease stroke; Genetic epidemiology; Vascular disease

Indexed keywords

PREALBUMIN; THYROXINE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC STABILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; THYROID FUNCTION; THYROXINE BLOOD LEVEL;

AMYLOID; AMYLOID ANGIOPATHY; CEREBROVASCULAR DISEASE/STROKE; GENETIC EPIDEMIOLOGY; VASCULAR DISEASE;

AGE DISTRIBUTION; AGED; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; CHROMOSOMAL INSTABILITY; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOMIC INSTABILITY; GENOTYPE; HUMANS; INCIDENCE; LIFE EXPECTANCY; LONGEVITY; MALE; MIDDLE AGED; PREALBUMIN; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 84879108709     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301273     Document Type: Article

References (43)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909.
2. Herbert J, Wilcox JN, Pham KT, Fremeau RT Jr, Zeviani M, Dwork A, Soprano DR, Makover A, Goodman DS, Zimmerman EA. Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology. 1986;36:900-911.
3. Fleming CE, Nunes AF, Sousa MM. Transthyretin: more than meets the eye. Prog Neurobiol. 2009;89:266-276.
4. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-Agency-Approved drug. J Mol Biol. 2012;421:185-203.
5. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109:9629-9634.
6. Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990;87:2843-2845.
7. Westermark P, Bergstrom J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid. 2003;10 suppl 1:48-54.
8. Pitkanen P, Westermark P, Cornwell GG III. Senile systemic amyloidosis. Am J Pathol. 1984;117:391-399.
9. Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75:618-623.
10. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232-239.
11. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation. 2011;124:1079-1085.
12. Benson MD. Amyloidosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:5345-5377.
13. Yamada M. Cerebral amyloid angiopathy: an overview. Neuropathology. 2000;20:8-22.
14. Almeida MR, Alves IL, Terazaki H, Ando Y, Saraiva MJ. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem Biophys Res Commun. 2000;270:1024-1028.
15. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW. The biological and chemical basis for tissueselective amyloid disease. Cell. 2005;121:73-85.
16. Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293:2459-2462.
17. Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299:713-716.
18. Terazaki H, Ando Y, Misumi S, Nakamura M, Ando E, Matsunaga N, Shoji S, Okuyama M, Ideta H, Nakagawa K, Ishizaki T, Ando M, Saraiva MJ. A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. Biochem Biophys Res Commun. 1999;264:365-370.
19. Almeida MR, Damas AM, Lans MC, Brouwer A, Saraiva MJ. Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine. 1997;6:309-315.
20. Curtis AJ, Scrimshaw BJ, Topliss DJ, Stockigt JR, George PM, Barlow JW. Thyroxine binding by human transthyretin variants: mutations at position 119, but not position 54, increase thyroxine binding affinity. J Clin Endocrinol Metab. 1994;78:459-462.
21. Alves IL, Divino CM, Schussler GC, Altland K, Almeida MR, Palha JA, Coelho T, Costa PP, Saraiva MJ. Thyroxine binding in a TTR Met 119 kindred. J Clin Endocrinol Metab. 1993;77:484-488.
22. Lim A, Prokaeva T, Connor LH, Falk RH, Skinner M, Costello CE. Identification of a novel transthyretin Thr59Lys/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis. Amyloid. 2002;9:134-140.
23. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal. 1999;13: 273-279.
24. Schussler GC. The thyroxine-binding proteins. Thyroid. 2000;10:141-149.
25. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785-792.
26. Harrison HH, Gordon ED, Nichols WC, Benson MD. Biochemical and clinical characterization of prealbuminCHICAGO: an apparently benign variant of serum prealbumin (transthyretin) discovered with high-resolution two-dimensional electrophoresis. Am J Med. Genet. 1991;39: 442-452.
27. Longo Alves I, Hays MT, Saraiva MJ. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur J Biochem. 1997;249:662-668.
28. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A. 1996;93:15051-15056.
29. Yamano M, Azuma A, Yazaki M, Ikeda S, Sawada T, Matsubara H. Early cardiac involvement in senile systemic amyloidosis: a case report. Amyloid. 2008;15:54-59.
30. Nakagawa M, Tojo K, Sekijima Y, Yamazaki KH, Ikeda S. Arterial thromboembolism in senile systemic amyloidosis: report of two cases. Amyloid. 2012;19:118-121.
31. Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, Frangione B. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002;12:343-357.
32. Li X, Buxbaum JN. Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener. 2011;6:79.
33. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A. 1994;91:8368-8372.
34. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A. 2008;105:2681-2686.
35. Fleming CE, Saraiva MJ, Sousa MM. Transthyretin enhances nerve regeneration. J Neurochem. 2007;103:831-839.
36. Santos SD, Lambertsen KL, Clausen BH, Akinc A, Alvarez R, Finsen B, Saraiva MJ. CSF transthyretin neuroprotection in a mouse model of brain ischemia. J Neurochem. 2010;115:1434-1444.
37. Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun. 2011;410:707-713.
38. Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 2013;52:1913-1926.
39. Ferreira N, Santos SA, Domingues MR, Saraiva MJ, Almeida MR. Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. Biochim Biophys Acta. 2013;1832:39-45.
40. Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models. PLoS One. 2012;7:-e29933.
41. Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012;101:805-813.
42. Mairal T, Nieto J, Pinto M, Almeida MR, Gales L, Ballesteros A, Barluenga J, Pérez JJ, Vázquez JT, Centeno NB, Saraiva MJ, Damas AM, Planas A, Arsequell G, Valencia G. Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS One. 2009;4:-e4124.
43. NHLBI Exome Sequencing Project (ESP) Exome Variant Server. http://evs.gs.washington.edu/EVS/. Accessed November 2012.